Press Releases
Momenta Pharmaceuticals Appoints Young T. Kwon As Vice President, Business Development
CAMBRIDGE, Mass., Jan. 4, 2011 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Young T. Kwon, Ph.D., has been appointed the Company's new Vice President of Business Development. Craig A. Wheeler, CEO of Momenta, commented, "We are delighted to have Young join our team. His valuable industry experience will be critical to us as we evaluate collaboration opportunities and execute on our business development initiatives. Building on his strong background in biologic products, Young will also play a key strategic leadership role as we advance our follow-on biologics product portfolio." Prior to joining Momenta, Dr. Kwon was Senior Director, Business Development, at Biogen Idec where he was responsible for leading corporate development activities, including evaluation of mergers and acquisitions, joint ventures and other strategic transactions. Prior to that, he identified and invested in early-stage life science companies at Advanced Technology Ventures. Dr. Kwon received his bachelor's degree in biology from the Massachusetts Institute of Technology and his Ph.D. in biological chemistry and molecular pharmacology from Harvard University. He has co-authored numerous peer-reviewed publications in the area of neurobiology. About Momenta Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA. To receive additional information about Momenta, please visit the website at www.momentapharma.com , which does not form a part of this press release. Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
CONTACT: Momenta Pharmaceuticals, Inc.
Beverly Holley, Director, Investor Relations
617-395-5189
bholley@momentapharma.com
TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.26
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |



Connect with TheStreet